▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #34 by analyst upside · 2026-11-14
JSPR
Jasper Therapeutics, Inc.
Healthcare · Market Cap $15M · P/E 0x
ANALYST PRICE TARGET
+4286.0%
implied upside to consensus target
Current Price $13.68
Consensus Target $600.0
Bull Target $600.0
Bear Target $600.0
Analysts Covering 1
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $9.45
52-Week High $72.6
YTD Return -75.2%
FUNDAMENTALS
Market Cap $15M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-31.92
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $9.45
52-Week High $72.6
Current Price $13.68
Bear Target $600.0
Bull Target $600.0
● Now $13.68 ● Target $600.0
TRADING DATA
Avg Volume 18K
YTD Return -75.2%
Analyst Count 1
Consensus Buy
Upside to Target +4286.0%
Last Updated 2026-11-14

ANALYST SUMMARY

Jasper Therapeutics, Inc. (JSPR) is currently trading at $13.68 with a Wall Street consensus price target of $600.0, implying potential upside of 4286.0% over the next 12 months. 1 analysts currently cover JSPR, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $600.0, while the most cautious has a target of $600.0.

JSPR operates in the Healthcare sector with a market capitalisation of $15M. The stock is down 75.2% year-to-date and is currently trading near the lower end of its 52-week range of $9.45 – $72.6.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

TOVX +2675.9%
Theriva Biologics, Inc.
$7M · P/E 0.2x · Buy
DWTX +1161.3%
Dogwood Therapeutics, Inc.
$42M · P/E 0.1x · Strong Buy
ETST +956.0%
Earth Science Tech, Inc.
$27M · P/E 9.5x · Hold
BBOT +949.3%
BridgeBio Oncology Therapeutics, Inc.
$172M · P/E 4.5x · Buy
NCEL +781.2%
NewcelX Ltd.
$15M · P/E 5.2x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for JSPR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler ● Initiated
Overweight 2026-08-12 14% win rate (7 calls)
TD Cowen ↓ Downgrade
Buy → Hold 2026-05-15 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-05-15 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-04-01 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2025-11-11 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2025-09-22 Building track record
JMP Securities - Reiterated
Market Outperform → Market Outperform 2025-09-22 Building track record
BTIG - Reiterated
Buy → Buy 2025-09-22 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →